Success Metrics

Clinical Success Rate
81.8%

Based on 9 completed trials

Completion Rate
82%(9/11)
Active Trials
0(0%)
Results Posted
89%(8 trials)
Terminated
2(18%)

Phase Distribution

Ph phase_1
3
27%
Ph phase_2
8
73%

Phase Distribution

3

Early Stage

8

Mid Stage

0

Late Stage

Phase Distribution11 total trials
Phase 1Safety & dosage
3(27.3%)
Phase 2Efficacy & side effects
8(72.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

81.8%

9 of 11 finished

Non-Completion Rate

18.2%

2 ended early

Currently Active

0

trials recruiting

Total Trials

11

all time

Status Distribution
Completed(9)
Terminated(2)

Detailed Status

Completed9
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
11
Active
0
Success Rate
81.8%
Most Advanced
Phase 2

Trials by Phase

Phase 13 (27.3%)
Phase 28 (72.7%)

Trials by Status

terminated218%
completed982%

Recent Activity

0 active trials
Showing 5 of 11
completedphase_1

Caspase Inhibition in Islet Transplantation

NCT01653899
completedphase_2

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

NCT02138253
completedphase_2

A Study of IDN-6556 in Subjects With Liver Cirrhosis

NCT02230670
completedphase_2

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

NCT02230683
terminatedphase_2

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

NCT01912404
View all 11 trials

Clinical Trials (11)

Showing 11 of 11 trials
NCT01653899Phase 1

Caspase Inhibition in Islet Transplantation

Completed
NCT02138253Phase 2

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

Completed
NCT02230670Phase 2

A Study of IDN-6556 in Subjects With Liver Cirrhosis

Completed
NCT02230683Phase 2

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Completed
NCT01912404Phase 2

Study of IDN-6556 in Patients With Severe Alcoholic Hepatitis and Contraindications to Steroid Therapy

Terminated
NCT02077374Phase 2

A Study of IDN-6556 in Subjects With NAFLD and Raised Transaminases

Completed
NCT01937130Phase 2

Pharmacokinetic and Pharmacodynamic Study of IDN-6556 in ACLF

Terminated
NCT02121860Phase 1

PK and PD Study of IDN-6556 in Subjects With Hepatic Impairment and Matched Healthy Volunteers

Completed
NCT02039817Phase 1

PK and PD Study of IDN-6556 in Subjects With Severe Renal Impairment and Matched Healthy Volunteers

Completed
NCT00088140Phase 2

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

Completed
NCT00080236Phase 2

Safety and Efficacy Study of a Caspase Inhibitor in Patients Undergoing Liver Transplantation

Completed

All 11 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
11